AGXT and hepatocellular carcinoma: Our group has recently implemented a novel PH1 cellular model based on HepG2 cells—a human cell line with conserved glyoxylate/oxalate metabolism derived from hepatocellular carcinoma—knocked out for the AGXT gene (AGXT-KO HepG2) using CRISPR/Cas9 technology (29).